Hepregen Corp. said Wednesday that it has named Martin J. Joyce as both vice president of finance and administration as well as CFO. Prior to joining Hepregen, Joyce was a member of Danforth Advisors group. Based in Medford, Mass., Hepregen Corp, which is backed by Battelle Venture Partners and Innovation Valley Partners, is a life science company focused on reducing the liver toxicity of existing pharmaceuticals.
MEDFORD, Mass.–(BUSINESS WIRE)–Hepregen Corporation, developer of next-generation HepatoPacTM and HepatoMuneTM products, announced today the appointment of Martin J. Joyce as Vice President of Finance and Administration and Chief Financial Officer. This appointment adds a highly experienced expert in finance to Hepregen’s senior management team. Mr. Joyce arrives at Hepregen as a member of Danforth Advisors group, a firm specializing in providing experienced finance and accounting personnel to emerging growth companies.
“His broad experience in international finance adds a particularly important capability to our execution effort.”
Mr. Joyce’s professional background includes C-level leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to those generating $500 million in annual revenue. He has extensive experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations.
“Hepregen has built a solid technical and scientific foundation already producing and selling first-generation products. The Company is poised to build a world-class commercial enterprise, comparable to any of the most successful companies with which I have been engaged,” stated Mr. Joyce.
“Hepregen is privileged to have Marty join our senior management team,” stated Dr. Vincent Zurawski, Hepregen’s Chief Executive Officer. “His broad experience in international finance adds a particularly important capability to our execution effort.”
About Hepregen Corporation
Hepregen Corporation is the undisputed leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic and diagnostic product development. The Company’s HepatoPacTM and HepatoMuneTM products support a potential paradigm shift in drug development. The utility of Hepregen’s human, rat, monkey and dog HepatoPacTM and HepatoMuneTM products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers and its academic and business partners. Hepregen was founded and capitalized by Battelle Venture Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications. She currently chairs the Company’s scientific advisory board. For more information, visit http://www.hepregen.com.
About Danforth Advisors
Danforth Advisors provides operational and strategic support services that enable life science and renewable energy companies across all growth stages—from inception through exit—to grow and optimize the value of their businesses. Danforth manages core operations and designs and executes corporate strategies and transactions. Danforth Advisors offers its accounting, financial, HR and other operational and strategic services on a part-time, interim, project, retainer, or advisory basis. For more information, visit http://www.danforthadvisors.com.